Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2014 (2014), Article ID 307202, 5 pages
http://dx.doi.org/10.1155/2014/307202
Clinical Study

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia

1University of Social Welfare and Rehabilitation Sciences (USWR), Razi Psychiatric Hospital, P.O. Box 18735-569, Tehran, Iran
2Razi Psychiatric Hospital, P.O. Box 18735-569, Tehran, Iran

Received 3 June 2014; Revised 14 August 2014; Accepted 15 August 2014; Published 26 August 2014

Academic Editor: Robin Emsley

Copyright © 2014 Saeed Shoja Shafti and Mahsa Gilanipoor. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Kane, “Schizophrenia,” The New England Journal of Medicine, vol. 334, no. 1, pp. 34–41, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Lieberman, “Prediction of outcome in first-episode schizophrenia,” Journal of Clinical Psychiatry, vol. 54, no. 3, pp. 13–17, 1993. View at Google Scholar · View at Scopus
  3. J. M. Kane and J. A. Lieberman, Adverse Effects of Psychotropic Drugs, Guilford Press, New York, NY, USA, 1992.
  4. S. Leucht, C. Corves, D. Arbter, R. R. Engel, C. Li, and J. M. Davis, “Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis,” The Lancet, vol. 373, no. 9657, pp. 31–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. A. Moore, N. C. Tye, M. S. Axton, and F. C. Risius, “The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent,” Journal of Pharmacology and Experimental Therapeutics, vol. 262, no. 2, pp. 545–551, 1992. View at Google Scholar · View at Scopus
  6. C. M. Beasley Jr., G. Tollefson, P. Tran, W. Satterlee, T. Sanger, and S. Hamilton, “Olanzapine versus placebo and haloperidol: Acute phase results of the North American Double-Blind Olanzapine Trial,” Neuropsychopharmacology, vol. 14, no. 2, pp. 111–123, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. G. D. Tollefson, C. M. Beasley Jr., P. V. Tran et al., “Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: results of an international collaborative trial,” The American Journal of Psychiatry, vol. 154, pp. 457–465, 1997. View at Google Scholar
  8. M. A. Dellva, P. Tran, G. D. Tollefson, A. L. Wentley, and C. M. Beasley Jr., “Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia,” Psychiatric Services, vol. 48, no. 12, pp. 1571–1577, 1997. View at Google Scholar · View at Scopus
  9. S. R. Marder and R. C. Meibach, “Risperidone in the treatment of schizophrenia,” American Journal of Psychiatry, vol. 151, no. 6, pp. 825–835, 1994. View at Google Scholar · View at Scopus
  10. P. V. Tran, S. H. Hamilton, A. J. Kuntz et al., “Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders,” Journal of Clinical Psychopharmacology, vol. 17, no. 5, pp. 407–418, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Gureje, W. Miles, N. Keks et al., “Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand,” Schizophrenia Research, vol. 61, no. 2-3, pp. 303–314, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. E. T. Edgell, S. W. Andersen, B. M. Johnstone, B. Dulisse, D. Revicki, and A. Breier, “Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia,” PharmacoEconomics, vol. 18, no. 6, pp. 567–579, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. K. L. Rascati, M. T. Johnsrud, M. L. Crismon, M. J. Lage, and B. L. Barber, “Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients,” PharmacoEconomics, vol. 21, no. 10, pp. 683–697, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. P. D. Feldman, C. J. Kaiser, J. S. Kennedy et al., “Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years,” The Journal of Clinical Psychiatry, vol. 64, no. 9, pp. 998–1004, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. D. M. Taylor, T. Wright, and S. E. Libretto, “Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis,” Journal of Clinical Psychiatry, vol. 64, no. 5, pp. 589–597, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Kasper, M. Jones, and I. Duchesne, “Risperidone olanzapine drug outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study,” International Clinical Psychopharmacology, vol. 16, no. 4, pp. 189–196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. R. R. Conley and R. Mahmoud, “A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder,” The American Journal of Psychiatry, vol. 158, no. 5, pp. 765–774, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Andreasen, The Scale for the Assessment of Negative Symptoms (SANS), University of Iowa, Department of Psychiatry, Iowa City, Iowa, USA, 1981.
  19. A. S. David, “Insight and psychosis,” British Journal of Psychiatry, vol. 156, pp. 798–808, 1990. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Guy, Ed., Clinical Global Impressions: ECDEU Assessment Manual for Psychopharmacology, Department of Health, Education, and Welfare, DHEW Publication, Rockville, Md, USA, 1976.
  21. G. M. Simpson and J. W. Angus, “A rating scale for extrapyramidal side effects,” Acta Psychiatrica Scandinavica, Supplement, vol. 212, supplement 44, pp. 11–19, 1970. View at Google Scholar · View at Scopus
  22. D. P. Van Kammen, S. R. Marder, and V. A. Sadock, “Serotonin-dopamin antagonists,” in Kaplan & Sadock's Comprehensive Textbook of Psychiatry, B. J. Sadock and V. A. Sadock, Eds., vol. 2, Lippincott Williams & Wilkins, Baltimore, Md, USA, 8th edition, 2005. View at Google Scholar
  23. B. C. Ho, D. Miller, P. Nopoulos, and N. C. Andreasen, “A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia,” Journal of Clinical Psychiatry, vol. 60, no. 10, pp. 658–663, 1999. View at Publisher · View at Google Scholar · View at Scopus